Stay updated on Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial
Sign up to get notified when there's something new on the Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial page.

Latest updates to the Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial page
- Check2 days agoNo Change Detected
- Check8 days agoChange DetectedThe Locations section was added and now lists California, Florida, Georgia, Indiana, Maryland, Michigan, Minnesota, Missouri, New Jersey, New York, North Carolina, Ohio, and Pennsylvania, with the revision tag updated to v3.3.3. Previous location subpages (e.g., California Locations, Florida Locations, etc.) were removed, and the HHS Vulnerability Disclosure link was removed.SummaryDifference1%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedA new revision label "Revision: v3.3.2" was added and the previous "Revision: v3.2.0" label was removed.SummaryDifference0.0%

- Check44 days agoChange DetectedThe notice about government funding status was removed, a non-substantive banner that does not affect the study details, eligibility, locations, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check59 days agoChange DetectedThe new screenshot shows minor UI updates and small data refinements to the study record (e.g., updated dates/locations) while the core study design and outcome information remain unchanged.SummaryDifference0.4%

- Check87 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision.SummaryDifference2%

- Check94 days agoChange DetectedRemoved a specific resource entry (Head and neck squamous cell carcinoma) and updated the page version to v3.1.0.SummaryDifference0.4%

Stay in the know with updates to Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial page.